Sheng Zhou
Wuhan, 430030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Correction: Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Journal: Angiogenesis
Published: October 16, 2025
STUB1 downregulates TOP2A through a dual mechanism of ubiquitination and FOXM1-mediated transcription repression, suppressing breast cancer growth and enhancing sensitivity to chemotherapy.
Journal: Cellular & molecular biology letters
Published: June 29, 2025
S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
Journal: Breast cancer research : BCR
Published: November 15, 2022
Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth.
Journal: Frontiers in pharmacology
Published: October 17, 2021
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.
Journal: Cancer chemotherapy and pharmacology
Published: September 12, 2020
Estrogen promotes the metastasis of non‑small cell lung cancer via estrogen receptor β by upregulation of Toll‑like receptor 4 and activation of the myd88/NF‑κB/MMP2 pathway.
Journal: Oncology reports
Published: August 24, 2019
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: May 11, 2019
Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Journal: Molecular carcinogenesis
Published: January 22, 2018
MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1.
Journal: Oncology letters
Published: August 21, 2017
Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Journal: Breast cancer research : BCR
Published: January 03, 2017
Last Updated: 09/26/2026